142 related articles for article (PubMed ID: 27322928)
1. Fatal Case of Primary Cutaneous Aggressive T-Cell Lymphoma Switching From a CD4+ to a CD8+ Phenotype: Progressive Disease With Bexarotene and Romidepsin Treatment.
Johnson WT; Leeman-Neill RJ; Patel P; Ho J; Grandinetti LM; Jedrych J; Craig FE
Am J Dermatopathol; 2016 Nov; 38(11):832-837. PubMed ID: 27322928
[TBL] [Abstract][Full Text] [Related]
2. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
[TBL] [Abstract][Full Text] [Related]
3. Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma.
Gormley RH; Hess SD; Anand D; Junkins-Hopkins J; Rook AH; Kim EJ
J Am Acad Dermatol; 2010 Feb; 62(2):300-7. PubMed ID: 19944484
[TBL] [Abstract][Full Text] [Related]
4. [Primary cutaneous aggressive epidermotropic cytotoxic CD8 positive T cell lymphoma: report of one case].
Intriago B M; Peña O C; Gray H AM; Cabrera C ME; Martínez C V
Rev Med Chil; 2012 Mar; 140(3):368-72. PubMed ID: 22689119
[TBL] [Abstract][Full Text] [Related]
5. Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy.
French LE; Shapiro M; Junkins-Hopkins JM; Vittorio CC; Rook AH
J Am Acad Dermatol; 2001 Dec; 45(6):914-8. PubMed ID: 11712039
[TBL] [Abstract][Full Text] [Related]
6. Leukaemic cutaneous T-cell lymphoma-manifesting papuloerythroderma with CD3(-) CD4(+) phenotype.
Shimauchi T; Sugita K; Nakamura M; Tokura Y
Acta Derm Venereol; 2010; 90(1):68-72. PubMed ID: 20107729
[TBL] [Abstract][Full Text] [Related]
7. CD4-CD8-"Double-negative" cutaneous T-cell lymphomas share common histologic features and an aggressive clinical course.
Jones D; Vega F; Sarris AH; Medeiros LJ
Am J Surg Pathol; 2002 Feb; 26(2):225-31. PubMed ID: 11812944
[TBL] [Abstract][Full Text] [Related]
8. Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences.
Bohmeyer J; Stadler R; Kremer A; Nashan D; Muche M; Gellrich S; Luger T; Sterry W
J Dtsch Dermatol Ges; 2003 Oct; 1(10):785-9. PubMed ID: 16281814
[TBL] [Abstract][Full Text] [Related]
9. Skin-homing CD8+ T lymphocytes show preferential growth in vitro and suppress CD4+ T-cell proliferation in patients with early stages of cutaneous T-cell lymphoma.
Thestrup-Pedersen K; Parhar R; Wu K; Bertilsson PA; Meyer B; Abu-Amero S; Hainau B; Aleisa A; Alfadley A; Hamadah I; Alajlan A; Al-Hussein K; Al-Mohanna F
Acta Derm Venereol; 2007; 87(2):118-26. PubMed ID: 17340017
[TBL] [Abstract][Full Text] [Related]
10. Six-year-old girl with primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma.
Kikuchi Y; Kashii Y; Gunji Y; Morimoto A; Masuzawa A; Takatsuka Y; Fujita E; Komine M; Ohtsuki M; Matsubara D; Kobayashi C; Sakurai A; Yanase K; Kato K; Koike K; Tsuchida M; Momoi MY
Pediatr Int; 2011 Jun; 53(3):393-6. PubMed ID: 21696508
[No Abstract] [Full Text] [Related]
11. Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathologic, immunophenotypic, and molecular study of 22 Asian cases according to WHO-EORTC classification.
Kong YY; Dai B; Kong JC; Zhou XY; Lu HF; Shen L; Du X; Shi DR
Am J Surg Pathol; 2008 Oct; 32(10):1495-502. PubMed ID: 18708940
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic hotline: Primary cutaneous CD4 + small/medium-sized pleomorphic T cell lymphoma coexisting with myelodysplastic syndrome transforming into chronic myelomonocytic leukemia successfully treated with cyclophosphamide.
Wawrzycki B; Chodorowska G; Pietrzak A; Jazienicka I; Skomra D; Kowal M; Dybiec E; Hercogova J
Dermatol Ther; 2010; 23(6):676-81. PubMed ID: 21054711
[TBL] [Abstract][Full Text] [Related]
13. Topical and oral bexarotene.
Schadt CR
Dermatol Ther; 2013; 26(5):400-3. PubMed ID: 24099070
[TBL] [Abstract][Full Text] [Related]
14. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior.
Berti E; Tomasini D; Vermeer MH; Meijer CJ; Alessi E; Willemze R
Am J Pathol; 1999 Aug; 155(2):483-92. PubMed ID: 10433941
[TBL] [Abstract][Full Text] [Related]
15. Clinical remission of primary aggressive CD8+ cutaneous T-cell lymphoma after pralatrexate infusion.
Kerdel FA; Styperek AR; Maini A
JAMA Dermatol; 2014 Mar; 150(3):320-2. PubMed ID: 24452280
[No Abstract] [Full Text] [Related]
16. Regression of extranodal natural killer/T-cell lymphoma, nasal type with denileukin diftitox (Ontak) and bexarotene (Targretin): report of a case.
Kerl K; Prins C; Cerroni L; French LE
Br J Dermatol; 2006 May; 154(5):988-91. PubMed ID: 16634908
[TBL] [Abstract][Full Text] [Related]
17. CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Français d'Etude des Lymphomes Cutanés (GFELC).
Petrella T; Dalac S; Maynadié M; Mugneret F; Thomine E; Courville P; Joly P; Lenormand B; Arnould L; Wechsler J; Bagot M; Rieux C; Bosq J; Avril MF; Bernheim A; Molina T; Devidas A; Delfau-Larue MH; Gaulard P; Lambert D
Am J Surg Pathol; 1999 Feb; 23(2):137-46. PubMed ID: 9989839
[TBL] [Abstract][Full Text] [Related]
18. Primary cutaneous CD4+ small- to medium-sized pleomorphic T-cell lymphoma: temporary remission by oral doxycycline.
Toberer F; Hartschuh W; Hadaschik E
JAMA Dermatol; 2013 Aug; 149(8):956-9. PubMed ID: 23760549
[TBL] [Abstract][Full Text] [Related]
19. Primary cutaneous small- to medium-sized CD4+ pleomorphic T-cell lymphoma: a retrospective case series and review of the provisional cutaneous lymphoma category.
Williams VL; Torres-Cabala CA; Duvic M
Am J Clin Dermatol; 2011 Dec; 12(6):389-401. PubMed ID: 21863906
[TBL] [Abstract][Full Text] [Related]
20. Primary cutaneous aggressive epidermotropic CD8+ T cell lymphoma with a chronic and indolent course. Is this different from peripheral T cell lymphoma?
Gomez Vazquez M; Navarra Amayuelas R
Dermatol Online J; 2012 Mar; 18(3):11. PubMed ID: 22483522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
